Predict your next investment

Private Equity
amzak.com/majalincapital

See what CB Insights has to offer

Investments

8

Portfolio Exits

2

About Amzak Health

The firm invests across the healthcare sector including therapeutics, devices, diagnostics and services. It sizes the investment based on the company’s needs, and seeks to invest a minimum of $5 million for venture capital deals and up to $75 million or more for growth equity transactions. It invests in both private and public companies.

Amzak Health Headquarter Location

295 Madison Avenue 32nd Floor

New York, New York, 10017,

United States

(212)242-2770

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Amzak Health News

LQT Therapeutics宣布结束美国1900万美元A轮融资,以推进先导化合物通过第一阶段,同时推进投资组合资产

Aug 11, 2021

LQT Therapeutics宣布结束美国1900万美元A轮融资,以推进先导化合物通过第一阶段,同时推进投资组合资产 本文共3094个字,阅读需8分钟 -  Company established with world-class research from leading academia and industry leaders-  Lead program targets a novel kinase involved in cellular stress response  -  Experienced and proven team advancing therapies for Long QT Syndrome and resistant cancersLAVAL, QC, Aug. 10, 2021 /PRNewswire/ - LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing. LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi S.A. (Paris, France) which inhibit Serum/Glucocorticoid Regulated Kinase 1 (SGK1). Recent research conducted by the company's founders confirmed the role of this novel kinase as a key contributor of inappropriate sodium regulation in various arrhythmias including Long QT Syndrome. Further investigation also validated the effects of SGK1 inhibition on cell proliferation pathways in prostate and colorectal cancers. Additional roles for upregulated activated SGK1 on various metabolic pathways continue to be discovered which LQTT intends to explore opportunistically. Over the past 12 months LQTT has successfully reproduced the positive effects of SGK1 inhibition in stem-cells of patients with Long QT Syndrome and various in vitro models of cell proliferation for prostate cancer and anticipates presenting this new data at an upcoming scientific conference. Based on this data LQTT has designated a series of promising SGK1 inhibitors for IND-enabling studies and eventual human use. Proceeds from this financing will advance and expand the company's portfolio of SGK1 inhibitors through phase 1 human clinical studies. "The enthusiasm from our investors is a reflection of breakthrough science, hard work and dedication of our scientists, founders and collaborators all sharing a vision to transform the lives of patients suffering from Long QT Syndrome and other devastating diseases," said Paul F. Truex, Chairman and Chief Executive Officer of LQT Therapeutics. "The investment of resources and expertise by our new shareholders and Sanofi's willingness to provide exclusive access to their intellectual property will be instrumental for us to advance our therapeutic programs. We are thankful for the efforts of our founders Dr. Anthony Rosenzweig, Dr. David Milan and Dr. Saumya Das, whose initial research uncovered this truly novel approach to treat rare arrhythmias and Dr. Marc Vidal who worked tirelessly over the past 18 months to advance our research while serving as a member of our Board of Directors. "The Series A financing was led by Amplitude Ventures and included new investments from Lumira Ventures, Amzak Health, Alexandria Venture Investments, founding investor Fonds de solidarité FTQ, founding scientists and members of the management team. As part of the financing Jean-François Pariseau from Amplitude, Daniel Hétu, MD from Lumira Ventures, and Scott Weiner from Amzak Health will join the Board of Directors. Additionally, Dr. Debra Odink will join the company as Chief Development Officer and Senior Vice President of Technical Operations. Having started her career at Roche, Dr. Odink spent the last 25 years in various leadership roles across multiple disease areas culminating in the successful commercialization of several pharmaceutical products and corporate outcomes. Dr. Philip Sager will join the company as Chief Medical Officer to provide regulatory and clinical development guidance to the company's lead program. Finally, Dr. Saumya Das, a founder will continue to provide clinical and scientific expertise to our Long QT Syndrome program. "Looking back at the progress that Paul, the founders and the LQTT team have made since we seeded this team in 2019 is so exciting," added Geneviève Guertin, Vice President for Investments, Life Sciences at Fonds de solidarité FTQ. "This project is the first of a new initiative in which the Fonds acts as a founding shareholder along with successful entrepreneurs. We are pleased to be joined today by such a great group of investors, with whom we will support LQTT into its next phase""We're excited to partner once again with this highly-skilled management team to support LQTT's goals in becoming a leader in precision cardiology", commented Jean-François Pariseau, co-founder and partner at Amplitude Ventures. "Rare and orphan cardiovascular diseases are a high need area—ideal for a more precision approach for diagnosis and treatment" Inquiries:  Info@lqttrx.comAbout LQT TherapeuticsLQT Therapeutics, Inc. is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias based on research from Beth Israel Deacons Medical Center, Massachusetts General Hospital, and Sanofi, S.A. By combining leading-edge cardiovascular genetics and diagnostics with recent advances in the understanding of the role of SGK1, LQT Therapeutics seeks to make a meaningful difference in the lives of people suffering from Long QT Syndrome and resistant cancers. Launched in 2019 by the Fonds de solidarité FTQ. LQT Therapeutics was founded by world-class experts in cardiovascular disease, cardiac muscle biology and drug development. For more information, please visit www.lqttrx.comAbout Our InvestorsAmplitude VenturesAmplitude is a full-stack venture capital firm using a unique growth model to build Canadian companies with world-class management teams and scale companies to breakout potential. With over $300M under management and offices in Montreal, Toronto and Vancouver, Amplitude applies a proven, evidence-based approach to investing in leading precision medicine companies. Visit www.amplitudevc.comThe Fonds de solidarité FTQThe Fonds de solidarité FTQ invests to build a better society by channeling the savings of its 723,501 shareholders into development and risk capital investments to help Québec transition to a green economy, to a human-centered world of work, and to a healthier society. The Fonds offers businesses unsecured financing and strategic support. With $17.2 billion in net assets as at May 31, 2021, the Fonds has supported 3,437 partner companies and 247,612 jobs. For more information, visit www.fondsftq.comLumira VenturesLumira Ventures is a North American healthcare venture capital firm with a two-decade track record of investing in transformative biomedical companies. It is a multi-stage investor that partners with mission-driven entrepreneurs and like-minded investors to build innovative companies in the biotechnology, medical device and digital health sectors. These companies are harnessing rapidly evolving innovations in genomics, cell therapy, gene therapy, bioengineering, robotics and artificial intelligence to develop high impact, often transformative products for patients while generating exceptional returns for their investors and meaningful economic value to society. To date, Lumira's companies have brought dozens of biomedical innovations to the market, impacting the lives of over 1 billion patients worldwide and generating over $70 billion of cumulative revenue. Lumira Ventures manages its activities from offices in Toronto, Montréal, Vancouver and Boston. For more information, please visit www.lumiraventures.com Amzak HealthAmzak Health is an evergreen fund that invests in private and select public life science companies across stages and geographies. It seeks to invest in innovative biotech and medtech companies developing first in class or best in class treatments addressing areas of unmet medical need. The Amzak Health team has significant investment and operating experience. Amzak Health approaches each investment with a long-term vision and prides itself on being knowledgeable and dependable partners. Amzak Heath is based in New York. https://amzak.comAlexandria Venture Investments Alexandria Venture Investments is the Alexandria Real Estate's strategic venture capital platform. Since its inception in 1996, it has invested in disruptive life science, agrifoodtech, and technology companies advancing transformative new modalities and platforms to meaningfully improve human health. www.are.commultimedia:https://www.prnewswire.com/news-releases/lqt-therapeutics-announces-closing-of-us19m-series-a-financing-to-advance-lead-compound-through-phase-1-while-advancing-portfolio-assets-301351917.html -公司成立时拥有来自领先学术界和行业领袖的世界级研究成果-Lead程序靶向一种参与细胞应激反应的新激酶-经验丰富、久经考验的团队推进治疗长QT综合征和耐药癌症QC拉瓦尔2021年8月10日电/PRNewswire/--LQT治疗公司(LQTT)是一家开创遗传性心脏病精准治疗开发的制药公司,今天宣布成功完成美国1900万美元的a轮融资。LQTT正在推进赛诺菲公司发现和开发的一系列许可化合物。(法国巴黎)抑制血清/糖皮质激素调节激酶1(SGK1)。该公司创始人最近进行的研究证实了这种新型激酶在包括长QT综合征在内的各种心律失常中作为钠调节不当的关键因素的作用。进一步的研究也证实了SGK1对前列腺癌和结直肠癌细胞增殖通路的抑制作用。另外的作用,上调激活的SGK1在各种代谢途径继续被发现,LQTT打算探索机会。在过去的12个月里,LQTT已经成功地在长QT综合征患者的干细胞中复制了SGK1抑制的积极作用,并在前列腺癌的各种体外细胞增殖模型中复制了SGK1抑制的积极作用,并期待在即将到来的科学会议上展示这一新数据。基于这些数据,LQTT已经指定了一系列有希望的SGK1抑制剂用于IND的研究和最终的人类使用。本次融资所得将通过1期人体临床研究推进和扩大公司的SGK1抑制剂组合。LQT Therapeutics董事长兼首席执行官保罗·特鲁克斯(Paul F.Truex)表示:“我们投资者的热情反映了突破性科学、我们的科学家、创始人和合作者的辛勤工作和奉献精神,他们都有一个共同的愿景,即改变患有长QT综合征和其他毁灭性疾病的患者的生活。”“我们的新股东对资源和专业知识的投资,以及赛诺菲提供独家访问他们知识产权的意愿,将有助于我们推进我们的治疗项目。我们感谢我们的创始人安东尼·罗森茨威格博士、大卫·米兰博士和绍米亚·达斯博士的努力,他们的初步研究发现了这种治疗罕见心律失常的真正新颖的方法,马克·维达尔博士在过去18个月里不知疲倦地工作,同时担任我们的董事会成员,以推进我们的研究。”A系列融资由振幅风险投资公司牵头,包括来自Lumira Ventures、Amzak Healtheal、Alexandria Venture investments、创始投资者Fonds de SolidaritéFTQ、创始科学家和管理团队成员的新投资。作为振幅的让-弗朗索瓦·帕里索(Jean-François Pariseau)融资的一部分,Lumira Ventures的医学博士丹尼尔·赫图(Daniel Hétu)和Amzak Health的斯科特·韦纳(Scott Weiner)将加入董事会。此外,黛布拉·奥丁克博士将作为首席开发官和技术运营高级副总裁加入公司。奥丁克博士在罗氏开始了她的职业生涯,在过去的25年里,她在多个疾病领域担任了各种领导角色,最终成功地将几种药物产品商业化,并取得了公司成果。Philip Sager博士将作为首席医疗官加入公司,为公司的领导项目提供监管和临床发展指导。最后,Saumya Das博士,一个创始人将继续为我们的长QT综合征项目提供临床和科学专业知识。“回顾保罗、创始人和LQTT团队自2019年加入该团队以来取得的进展,令人兴奋,”FTQ基金会负责投资和生命科学的副总裁热内维夫·盖尔廷补充道。这个项目是Fonds作为创始股东和成功企业家的第一个新项目。我们很高兴今天有这么多投资者加入,我们将与他们一起支持LQTT进入下一阶段。“振幅风险投资公司的联合创始人兼合伙人让-弗朗索瓦·帕里索(Jean-François Pariseau)评论说:“我们很高兴再次与这支高技能的管理团队合作,支持LQTT成为精密心脏病学领导者的目标。”“罕见和孤儿心血管疾病是一个高需求领域--理想的更精确的诊断和治疗方法”咨询:info@lqttrx.com关于LQT疗法LQT治疗公司正在开创一种精准医学方法,以治疗长QT综合征和潜在的其他心律失常的患者,基于贝丝·伊斯雷尔·迪肯医疗中心、马萨诸塞州总医院和赛诺菲公司的研究。通过将前沿的心血管遗传学和诊断学与最近对SGK1作用的理解进展相结合,LQT疗法寻求对患有长QT综合征和耐药癌症的人的生活产生有意义的影响。由FTQ团结基金于2019年推出。LQT Therapeutics由心血管疾病、心肌生物学和药物开发方面的世界级专家创立。欲了解更多信息,请访问www.lqttrx.com关于我们的投资者振幅冒险振幅是一家全栈风险投资公司,采用独特的增长模式,建立具有世界级管理团队和规模公司的加拿大公司,以突破潜力。在蒙特利尔、多伦多和温哥华设有办事处,旗下管理着超过3亿美元的资产。在投资领先的精准医疗公司时,波幅采用了一种经过验证的、基于证据的方法。访问www.amplitudevc.comFonds de SolidaritéFTQFonds de SolidaritéFTQ投资建设一个更美好的社会,将其723,501名股东的储蓄用于发展和风险资本投资,帮助魁北克向绿色经济、以人为本的工作世界和更健康的社会过渡。Fonds为企业提供无担保融资和战略支持。截至2021年5月31日,基金净资产为172亿美元,已支持3437家合作公司和247,612个工作岗位。欲了解更多信息,请访问www.fondsftq.comLumira VenturesLumira Ventures是一家北美医疗保健风险投资公司,有20年投资变革性生物医药公司的记录。它是一个多阶段的投资者,与使命驱动的企业家和志同道合的投资者合作,在生物技术、医疗设备和数字健康领域建立创新公司。这些公司正在利用基因组学、细胞治疗、基因治疗、生物工程、机器人技术和人工智能等领域迅速发展的创新,为患者开发高影响力、往往是变革性的产品,同时为投资者带来非凡的回报,并为社会带来有意义的经济价值。迄今为止,Lumira的公司已经为市场带来了数十项生物医学创新,影响了全球超过10亿患者的生活,并创造了超过700亿美元的累计收入。Lumira Ventures在多伦多、蒙特雷、温哥华和波士顿的办事处管理其活动。欲了解更多信息,请访问www.lumiraventures.com阿姆扎克健康Amzak Health是一个常青基金,投资于私人和跨阶段和地理位置选择公共生命科学公司。它寻求投资于创新的生物技术和医疗技术公司,开发一流或一流的治疗方法,解决未满足的医疗需求。Amzak健康团队拥有丰富的投资和运营经验。Amzak Health以长远眼光对待每一项投资,并以自己是知识渊博、可靠的合作伙伴而自豪。阿姆扎克·希思总部设在纽约。https://amzak.com亚历山大风险投资公司亚历山大风险投资是亚历山大房地产的战略风险投资平台。自1996年成立以来,它投资于颠覆性生命科学、农业食品技术和技术公司,推动变革性新模式和平台,以有意义地改善人类健康。www.are.com多媒体:https://www.prnewswire.com/news-releases/lqt-therapeutics-announces-closing-of-us19m-series-a-financing-to-advance-lead-compound-through-phase-while-advancing-portfolio-assets-301351917.html 以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

Amzak Health Investments

8 Investments

Amzak Health has made 8 investments. Their latest investment was in Gynesonics as part of their Series G on December 12, 2021.

CBI Logo

Amzak Health Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/29/2021

Series G

Gynesonics

$32.5M

Yes

11/3/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

8/10/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/12/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

3/12/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/29/2021

11/3/2021

8/10/2021

4/12/2021

3/12/2021

Round

Series G

Series B - II

Series A

Series B

Series C

Company

Gynesonics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$32.5M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

10

10

10

Amzak Health Portfolio Exits

2 Portfolio Exits

Amzak Health has 2 portfolio exits. Their latest portfolio exit was Monte Rosa Therapeutics on June 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/24/2021

IPO

$99M

Public

17

4/9/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/24/2021

4/9/2021

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

17

10

Amzak Health Team

1 Team Member

Amzak Health has 1 team member, including current Managing Partner, Joyce Erony.

Name

Work History

Title

Status

Joyce Erony

Managing Partner

Current

Name

Joyce Erony

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.